Literature DB >> 2847413

Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein 1.

P Cassinotti1, M Weitz, J D Tratschin.   

Abstract

We have mapped a minor spliced transcript with mRNA properties which is derived from the capsid gene promoter (P40) of the adeno-associated virus (AAV) genome. By S1 nuclease mapping as well as primer extension analysis this mRNA was found to occur by splicing at the same donor site (nucleotide, NT 1907) but at an alternative acceptor site when compared to the major, 2.3-kb spliced P40 transcript which encodes two of the three AAV capsid proteins, namely VP2 and VP3. This minor acceptor site is located at NT 2200, i.e., 27 NT upstream of the acceptor site used to generate the VP2/VP3 mRNA. We have also sequenced the AAV genome in this region and have found one important error in the sequence published by A. Srivastava, E. Lusby, and K.I. Berns (1983, J. Virol., 45, 555-564): residue at NT 2429 has to be deleted from the reported sequence. This correction of the sequence reveals that the open reading frame (ORF) which encodes all three capsid proteins extends from NT 2203 to NT 4321. Furthermore, this entire ORF is contained in the minor but not in the major spliced P40 transcript. We provide evidence that the largest AAV structural protein VP1 is translated from this hitherto undetected spliced transcript by initiation at its first AUG (NT 2203) and termination at NT 4321. The calculated molecular weight of this VP1 polypeptide is 78,247 Da.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847413

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size.

Authors:  G E Tullis; T Shenk
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 2.  Parvovirus replication.

Authors:  K I Berns
Journal:  Microbiol Rev       Date:  1990-09

Review 3.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

4.  Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep proteins.

Authors:  S Weger; A Wistuba; D Grimm; J A Kleinschmidt
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging.

Authors:  Svenja Bleker; Michael Pawlita; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  A viral assembly factor promotes AAV2 capsid formation in the nucleolus.

Authors:  Florian Sonntag; Kristin Schmidt; Jürgen A Kleinschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

7.  Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses.

Authors:  U Bantel-Schaal; H Delius; R Schmidt; H zur Hausen
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 8.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

9.  Identification of a heparin-binding motif on adeno-associated virus type 2 capsids.

Authors:  A Kern; K Schmidt; C Leder; O J Müller; C E Wobus; K Bettinger; C W Von der Lieth; J A King; J A Kleinschmidt
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Non-structural proteins of Periplaneta fuliginosa densovirus inhibit cellular gene expression and induce necrosis in Sf9 cell cultures.

Authors:  Bo Yang; Dawei Cai; Peiran Yu; Xiaomin Dong; Zhigang Liu; Zheng Hu; Xu Cao; Jiamin Zhang; Yuanyang Hu
Journal:  Virus Genes       Date:  2009-03-18       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.